secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-011941
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B
-------------------------------------------------------------------------

- Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).
- GAAP net income $286.9M vs loss $644.8M prior year; diluted EPS $2.53 vs loss $6.12.
- BRUKINSA global sales $3.9B (+49% YoY); Q4 sales $1.1B (+38%).
- Non-GAAP diluted EPS $8.09; Adjusted income from operations $1.1B from $45M prior year.
- FY2026 revenue guidance $6.2B-$6.4B; management cites pipeline strength and global leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/0001628280-26-011941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/bgne-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer